Phase I open-label dose escalation trial evaluating the safety and immunogenicity of sequential administration of recombinant DNA and adenovirus expressing L523S protein [lung cancer vaccine] in patients with early stage non-small cell lung cancer

Trial Profile

Phase I open-label dose escalation trial evaluating the safety and immunogenicity of sequential administration of recombinant DNA and adenovirus expressing L523S protein [lung cancer vaccine] in patients with early stage non-small cell lung cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lung cancer vaccine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Corixa Corporation
  • Most Recent Events

    • 08 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top